PulseSight Therapeutics Raises Seed Funding
PulseSight Therapeutics, a Paris, France-based ophthalmology biotech company, raised an undisclosed amount in Seed funding.
PulseSight Therapeutics, a Paris, France-based ophthalmology biotech company, raised an undisclosed amount in Seed funding.
Photoroom, a Paris, France-based AI photo editor, raised $43M in Series B funding.
Ouinex, a Paris, France-based provider of a digital assets trading platform, raised over $4M in funding.
AZmed, a Paris, France-based MedTech startup providing AI-powered radiology software, raised €15M in funding.
Bioptimus, a Paris, France-based biotechnology company providing an AI foundation model for the research, raised $35M in funding.
ShortPixel, a Bucharest, Romania-based image optimization company, acquired ReSmush.it, a French provider of free image optimization tools.
Avatar Merdical, a Paris, France-, and Mountain View, CA-based company providing a real-time solution for surgeons to engage with patients, raised €5M in Seed funding.
Groover, a Paris, France-based provider of a music promotion platform, raised $8M in Series A funding.
Trading Technologies (TT), a Chicago, IL-based global capital markets technology platform provider, acquired Ateo, a Paris, France-based provider of post-trade solutions for listed derivatives.
Jow, a Paris, France-based provider of a grocery shopping and menu recommendation app, raised $13m in additional funding.
Pixee Medical, a Besaçon, France-based company providing reality navigation technologies for orthopedic surgery, raised $15M in funding.
Pennylane, a Paris, France-based fintech company, raised €40M in Series C funding.
Essence, a Paris, France-based startup that elevates the performance of female employees by optimizing their schedule according to the hormonal cycle, raised $600K in funding.
Twin Labs, a Paris, France-based developer of an automation tool to handle repetitive tasks, raised $3m in pre-seed funding.
Vivet Therapeutics, a Paris, France-based clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders, received EUR 4.9M in funding.